← Browse by Condition
Medical Condition
esophageal squamous cell carcinoma
Total Trials
12
Recruiting Now
12
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
NCT06885814 Phase 2
Recruiting
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
Enrollment
30 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
NCT05490719 Phase 2
Recruiting
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Enrollment
39 pts
Location
China
Sponsor
Tianjin Medical University Can...
NCT07284186 Phase 1
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Enrollment
155 pts
Location
United States
Sponsor
Plexium, Inc.
NCT06047379 Phase 1, Phase 2
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Enrollment
134 pts
Location
United States
Sponsor
Neonc Technologies, Inc.
NCT06684600 Phase 2
Recruiting
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Enrollment
35 pts
Location
China
Sponsor
Peking University
NCT06186609 Phase 2
Recruiting
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Enrollment
68 pts
Location
China
Sponsor
Affiliated Hospital of Nantong...
NCT06173986 Phase 1, Phase 2
Recruiting
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Enrollment
50 pts
Location
China
Sponsor
Shanghai Chest Hospital
NCT03964753 Phase 2
Recruiting
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
Enrollment
202 pts
Location
China
Sponsor
Hebei Medical University Fourt...
NCT06056336 Phase 2
Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Enrollment
73 pts
Location
China
Sponsor
Guo Xufeng
NCT06780111 Phase 1, Phase 2
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Enrollment
298 pts
Location
United States, Brazi...
Sponsor
Merck Sharp & Dohme LLC
NCT05252078 Phase 2
Recruiting
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
Enrollment
30 pts
Location
China
Sponsor
Jiangxi Provincial Cancer Hosp...
NCT06654297 Phase 1
Recruiting
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
Enrollment
6 pts
Location
China
Sponsor
West China Hospital